Guggenheim assumed coverage on shares of Horizon Therapeutics (NASDAQ:HZNP) in a report published on Thursday, BenzingaRatingsTable reports. The firm issued a buy rating and a $36.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on HZNP. ValuEngine cut Horizon Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 5th. BidaskClub cut Horizon Therapeutics from a buy rating to a hold rating in a research report on Friday, September 6th. Cowen set a $35.00 price objective on Horizon Therapeutics and gave the company a buy rating in a research report on Wednesday, August 7th. TheStreet cut Horizon Therapeutics from a b- rating to a c+ rating in a research report on Monday, June 10th. Finally, BMO Capital Markets upgraded Horizon Therapeutics from a market perform rating to an outperform rating and boosted their price objective for the company from $29.00 to $36.00 in a research report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $33.00.

HZNP stock traded down $0.09 during trading on Thursday, hitting $26.34. 1,297,916 shares of the company traded hands, compared to its average volume of 1,792,502. The stock’s 50-day simple moving average is $26.34 and its 200 day simple moving average is $25.61. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12. The company has a market cap of $4.93 billion, a PE ratio of 14.45, a P/E/G ratio of 1.55 and a beta of 0.77. Horizon Therapeutics has a 1 year low of $16.56 and a 1 year high of $29.44.

Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.14. The company had revenue of $320.60 million during the quarter, compared to analysts’ expectations of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. Horizon Therapeutics’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.48 earnings per share. Research analysts expect that Horizon Therapeutics will post 1.6 earnings per share for the current year.

In other news, EVP Geoffrey M. Curtis sold 20,609 shares of Horizon Therapeutics stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $26.58, for a total value of $547,787.22. Following the sale, the executive vice president now directly owns 28,382 shares of the company’s stock, valued at $754,393.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vikram Karnani sold 13,111 shares of Horizon Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $25.02, for a total value of $328,037.22. The disclosure for this sale can be found here. Insiders sold 235,278 shares of company stock worth $6,473,106 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Several large investors have recently modified their holdings of HZNP. FMR LLC boosted its stake in shares of Horizon Therapeutics by 165.1% in the first quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock worth $137,575,000 after acquiring an additional 3,242,071 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Horizon Therapeutics by 1,910.0% in the second quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock worth $40,249,000 after acquiring an additional 1,589,614 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Horizon Therapeutics in the first quarter worth approximately $27,663,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Horizon Therapeutics by 1,774.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock worth $26,508,000 after acquiring an additional 1,042,969 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Horizon Therapeutics by 11.4% in the second quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock worth $210,628,000 after acquiring an additional 896,500 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Further Reading: Are analyst ratings accurate?

Analyst Recommendations for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.